NEW YORK, July 2, 2012 /PRNewswire/ -- Attorney
Advertising -- Bronstein, Gewirtz & Grossman, LLC is
investigating potential claims against the Board of Directors of
Amylin Pharmaceuticals, Inc. ("Amylin" or the "Company") (NsadaqGS:
AMLN) related to the proposed acquisition of the Company by
Bristol-Myers Squibb Company. The transaction is valued at
approximately $5.3 billion or
$31 per share.
This investigation concerns whether the Board of Directors of
Amylin breached their fiduciary duties to stockholders by failing
to adequately shop the Company before agreeing to enter into the
proposed transaction, and whether the Company has disclosed all
material information to shareholders about the transaction.
Bristol said late Friday it would
pay $31 a share to snatch up
Amylin. The offer represents a 9.9% premium to Amylin's
closing price Friday of $28.20 a
share.
If you are aware of any facts relating to this investigation, or
purchased shares of Amylin, you can assist this investigation by
contacting either Peretz Bronstein
or Eitan Kimelman of Bronstein,
Gewirtz & Grossman, LLC at 212-697-6484 or via email
eitan@bgandg.com. Those who inquire by e-mail are encouraged to
include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman, 212-697-6484
eitan@bgandg.com
SOURCE Bronstein, Gewirtz & Grossman, LLC